Literature DB >> 23838419

Dopaminergic modulation of memory and affective processing in Parkinson depression.

Lee X Blonder1, John T Slevin, Richard J Kryscio, Catherine A Martin, Anders H Andersen, Charles D Smith, Frederick A Schmitt.   

Abstract

Depression is common in Parkinson's disease and is associated with cognitive impairment. Dopaminergic medications are effective in treating the motor symptoms of Parkinson's disease; however, little is known regarding the effects of dopaminergic pharmacotherapy on cognitive function in depressed Parkinson patients. This study examines the neuropsychological effects of dopaminergic pharmacotherapy in Parkinsonian depression. We compared cognitive function in depressed and non-depressed Parkinson patients at two time-points: following overnight withdrawal and after the usual morning regimen of dopaminergic medications. A total of 28 non-demented, right-handed patients with mild to moderate idiopathic Parkinson's disease participated. Ten of these patients were depressed according to DSM IV criteria. Results revealed a statistically significant interaction between depression and medication status on three measures of verbal memory and a facial affect naming task. In all cases, depressed Parkinson's patients performed significantly more poorly while on dopaminergic medication than while off. The opposite pattern emerged for the non-depressed Parkinson's group. The administration of dopaminergic medication to depressed Parkinson patients may carry unintended risks.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Dopamine; Emotion; Mood; Parkinson

Mesh:

Substances:

Year:  2013        PMID: 23838419      PMCID: PMC3805794          DOI: 10.1016/j.psychres.2013.06.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  47 in total

1.  Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.

Authors:  Alessandro Tessitore; Ahmad R Hariri; Francesco Fera; William G Smith; Thomas N Chase; Thomas M Hyde; Daniel R Weinberger; Venkata S Mattay
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.

Authors:  J Kulisevsky; C García-Sánchez; M L Berthier; M Barbanoj; B Pascual-Sedano; A Gironell; A Estévez-González
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

3.  Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.

Authors:  M H Corrigan; A Q Denahan; C E Wright; R J Ragual; D L Evans
Journal:  Depress Anxiety       Date:  2000       Impact factor: 6.505

Review 4.  Catechol-O-methyltransferase and Parkinson's disease.

Authors:  Chun-Hwi Tai; Ruey-Meei Wu
Journal:  Acta Med Okayama       Date:  2002-02       Impact factor: 0.892

5.  Depressed mood and executive dysfunction in early Parkinson's disease.

Authors:  J Uekermann; I Daum; S Peters; B Wiebel; H Przuntek; T Müller
Journal:  Acta Neurol Scand       Date:  2003-05       Impact factor: 3.209

6.  Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands.

Authors:  R Cools; R A Barker; B J Sahakian; T W Robbins
Journal:  Cereb Cortex       Date:  2001-12       Impact factor: 5.357

7.  Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.

Authors:  Roshan Cools; Elka Stefanova; Roger A Barker; Trevor W Robbins; Adrian M Owen
Journal:  Brain       Date:  2002-03       Impact factor: 13.501

8.  Dopaminergic modulation of cortical function in patients with Parkinson's disease.

Authors:  Venkata S Mattay; Alessandro Tessitore; Joseph H Callicott; Alessandro Bertolino; Terry E Goldberg; Thomas N Chase; Thomas M Hyde; Daniel R Weinberger
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

9.  Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism.

Authors:  Mary-Anne Enoch; Ke Xu; Erica Ferro; Claudia R Harris; David Goldman
Journal:  Psychiatr Genet       Date:  2003-03       Impact factor: 2.458

10.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Authors:  J G Nutt; K J Burchiel; C L Comella; J Jankovic; A E Lang; E R Laws; A M Lozano; R D Penn; R K Simpson; M Stacy; G F Wooten
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

View more
  5 in total

1.  Meta-analyses of seven GIGYF2 polymorphisms with Parkinson's disease.

Authors:  Dongjun Dai; Yunliang Wang; Xingyu Zhou; Jianmin Tao; Danjie Jiang; Hanlin Zhou; Yi Jiang; Guanghui Pan; Ping Ru; Huihui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Mingqing Xu; Shiwei Duan
Journal:  Biomed Rep       Date:  2014-07-31

2.  Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.

Authors:  Brenda Hanna-Pladdy; Rajesh Pahwa; Kelly E Lyons
Journal:  J Int Neuropsychol Soc       Date:  2015-04-29       Impact factor: 2.892

3.  Polymorphisms of DRD2 and DRD3 genes and Parkinson's disease: A meta-analysis.

Authors:  Dongjun Dai; Yunliang Wang; Lingyan Wang; Jinfeng Li; Qingqing Ma; Jianmin Tao; Xingyu Zhou; Hanlin Zhou; Yi Jiang; Guanghui Pan; Limin Xu; Ping Ru; Danfeng Lin; Jun Pan; Leiting Xu; Meng Ye; Shiwei Duan
Journal:  Biomed Rep       Date:  2014-01-13

4.  Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression.

Authors:  Anders H Andersen; Charles D Smith; John T Slevin; Richard J Kryscio; Catherine A Martin; Frederick A Schmitt; Lee X Blonder
Journal:  Parkinsons Dis       Date:  2015-12-17

5.  Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.

Authors:  Veronica Antipova; Carsten Holzmann; Alexander Hawlitschka; Martin Witt; Andreas Wree
Journal:  Toxins (Basel)       Date:  2021-07-20       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.